This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Loy, J. K. Articles by Durham, S. K. Search for Related Content PubMed PubMed Citation Articles by Loy, J. K. Articles by Durham, S. K. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Oncostatin M: Development of a Pleiotropic Cytokine

Department of Experimental Pathology, Bristol-Myers Squibb, Princeton, New Jersey

Thomas J. Davidson

Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York

Karen K. Berry

Animal Modeling, Bristol-Myers Squibb, Princeton, New Jersey

John F. Macmaster

Animal Modeling, Bristol-Myers Squibb, Princeton, New Jersey

Bharat Danle

Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York

Stephen K. Durham

Department of Experimental Pathology, Bristol-Myers Squibb, Princeton, New Jersey

Oncostatin M (OM) is a member of the interleukin-6 (IL-6) cytokine subfamily. The binding of OM to its receptor initiates signal transduction through JAK-signal transducers and activators of transcription (STAT) pathways and activates transcription activators through mitogen-activated protein (MAP) kinases. Results of in vitro assays documented that OM modulates cytokine expression and alters the production of proteases that down-regulate inflammation. Administration of OM to lipopolysaccharide (LPS)-challenged mice lowered serum tumor necrosis factor- (TNF-) levels and decreased the lethal effects of LPS administration. OM also reduced inflammation in animal models of human disease, including inflammatory bowel disease, antibody-induced arthritis, and experimental autoimmune encephalomyelitis. Preclinical safety studies have been conducted in the mouse and monkey. Mice were administered OM (subcutaneously) at 72, 360, or 1,560 µg/kg/day in a 2-wk toxicity study. Decreased body weights occurred at 1,560 µg/kg. Drug-related changes at 360 and 1,560 µg/kg consisted of dermal irritation at the injection site, leukopenia, and thymic lymphoid depletion; all changes were reversible following a 2-wk recovery period. In a 2-wk subcutaneous study in monkeys, OM was administered at 1, 5, 15, 45, or 150 µg/kg/day. At all doses there was reversible, transient inappetence and dermal irritation at the injection site. Drug-related changes at 5, 15, 45, and 150 µg/kg consisted of reversible elevations in both serum amyloid A and IL-6, and reversible thymic lymphoid depletion. Transient increases in body temperature occurred at 15, 45, and 150 µg/kg. The observed spectrum of immunomodulatory effects suggests that OM may have therapeutic utility in treating chronic inflammatory diseases.

Key Words: Interleukin-61 inflammation • anti-inflammatory • immunomodulatory • safety assessment

Toxicologic Pathology, Vol. 27, No. 2, 151-155 (1999)
DOI: 10.1177/019262339902700201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V. N. Bochkov, G. Maurer, K. Huber, and J. Wojta The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1962 - H1968. [Abstract] [Full Text] [PDF]

				G. Rega, C. Kaun, T.W. Weiss, S. Demyanets, G. Zorn, S.P. Kastl, S. Steiner, D. Seidinger, C.W. Kopp, M. Frey, et al. Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue Circulation, April 19, 2005; 111(15): 1938 - 1945. [Abstract] [Full Text] [PDF]

				C. Boileau, M. Houde, G. Dulude, C. H. Clegg, and C. Perreault Regulation of Extrathymic T Cell Development and Turnover by Oncostatin M J. Immunol., June 1, 2000; 164(11): 5713 - 5720. [Abstract] [Full Text] [PDF]

				Y. Wang, O. Robledo, E. Kinzie, F. Blanchard, C. Richards, A. Miyajima, and H. Baumann Receptor Subunit-specific Action of Oncostatin M in Hepatic Cells and Its Modulation by Leukemia Inhibitory Factor J. Biol. Chem., August 11, 2000; 275(33): 25273 - 25285. [Abstract] [Full Text] [PDF]